Imatinib is a TKI for Bcr-Abl, c-Kit, c-Abl, and PDGF receptor signaling, and has been used for the treatment of chronic myelogenous leukemia and gastrointestinal stromal tumors [29]. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.